Source:http://linkedlifedata.com/resource/pubmed/id/12086933
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2002-6-27
|
pubmed:abstractText |
Specialized neurons utilize glucose as a signaling molecule to alter their firing rate. Glucose-excited (GE) neurons increase and glucose-inhibited (GI) neurons reduce activity as ambient glucose levels rise. Glucose-induced changes in the ATP-to-ADP ratio in GE neurons modulate the activity of the ATP-sensitive K(+) channel, which determines the rate of cell firing. The GI glucosensing mechanism is unknown. We postulated that glucokinase (GK), a high-Michaelis constant (K(m)) hexokinase expressed in brain areas containing populations of GE and GI neurons, is the controlling step in glucosensing. Double-label in situ hybridization demonstrated neuron-specific GK mRNA expression in locus ceruleus norepinephrine and in hypothalamic neuropeptide Y, pro-opiomelanocortin, and gamma-aminobutyric acid neurons, but it did not demonstrate this expression in orexin neurons. GK mRNA was also found in the area postrema/nucleus tractus solitarius region by RT-PCR. Intracarotid glucose infusions stimulated c-fos expression in the same areas that expressed GK. At 2.5 mmol/l glucose, fura-2 Ca(2+) imaging of dissociated ventromedial hypothalamic nucleus neurons demonstrated GE neurons whose intracellular Ca(2+) oscillations were inhibited and GI neurons whose Ca(2+) oscillations were stimulated by four selective GK inhibitors. Finally, GK expression was increased in rats with impaired central glucosensing (posthypoglycemia and diet-induced obesity) but was unaffected by a 48-h fast. These data suggest a critical role for GK as a regulator of glucosensing in both GE and GI neurons in the brain.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0012-1797
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
51
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2056-65
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12086933-Animals,
pubmed-meshheading:12086933-Brain,
pubmed-meshheading:12086933-Carotid Artery, Internal,
pubmed-meshheading:12086933-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:12086933-Genes, fos,
pubmed-meshheading:12086933-Glucokinase,
pubmed-meshheading:12086933-Glucose,
pubmed-meshheading:12086933-In Situ Hybridization,
pubmed-meshheading:12086933-Infusions, Intra-Arterial,
pubmed-meshheading:12086933-Neurons,
pubmed-meshheading:12086933-Obesity,
pubmed-meshheading:12086933-Rats,
pubmed-meshheading:12086933-Rats, Sprague-Dawley,
pubmed-meshheading:12086933-Transcription, Genetic,
pubmed-meshheading:12086933-Weight Gain
|
pubmed:year |
2002
|
pubmed:articleTitle |
Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons.
|
pubmed:affiliation |
Neurology Service, Department of Veterans Affairs Medical Center, 385 Tremont Avenue, East Orange, NJ 07018-1095, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|